CN110520418B - Ampa受体增强剂 - Google Patents
Ampa受体增强剂 Download PDFInfo
- Publication number
- CN110520418B CN110520418B CN201880023973.3A CN201880023973A CN110520418B CN 110520418 B CN110520418 B CN 110520418B CN 201880023973 A CN201880023973 A CN 201880023973A CN 110520418 B CN110520418 B CN 110520418B
- Authority
- CN
- China
- Prior art keywords
- disorder
- compound
- alkyl
- compounds
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1702221.1 | 2017-02-10 | ||
| GBGB1702221.1A GB201702221D0 (en) | 2017-02-10 | 2017-02-10 | Compounds |
| PCT/GB2018/050370 WO2018146486A1 (en) | 2017-02-10 | 2018-02-09 | Ampa receptor potentiators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110520418A CN110520418A (zh) | 2019-11-29 |
| CN110520418B true CN110520418B (zh) | 2022-08-16 |
Family
ID=58462168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880023973.3A Active CN110520418B (zh) | 2017-02-10 | 2018-02-09 | Ampa受体增强剂 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11186567B2 (OSRAM) |
| EP (1) | EP3580213B1 (OSRAM) |
| JP (1) | JP7014808B2 (OSRAM) |
| KR (1) | KR102665887B1 (OSRAM) |
| CN (1) | CN110520418B (OSRAM) |
| AU (1) | AU2018218307C1 (OSRAM) |
| ES (1) | ES2974824T3 (OSRAM) |
| GB (1) | GB201702221D0 (OSRAM) |
| MX (1) | MX2019009537A (OSRAM) |
| NZ (1) | NZ755747A (OSRAM) |
| RU (1) | RU2019126574A (OSRAM) |
| WO (1) | WO2018146486A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
| WO2024255822A1 (zh) * | 2023-06-15 | 2024-12-19 | 上海魁特迪生物科技有限公司 | Dir结合剂及其用途 |
| CN121652294A (zh) * | 2026-02-06 | 2026-03-13 | 首都医科大学宣武医院 | 一种用于检测抗ampar1抗体的融合蛋白及其用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008053031A1 (en) * | 2006-11-03 | 2008-05-08 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| WO2008148832A1 (en) * | 2007-06-08 | 2008-12-11 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses therof in medicine |
| WO2008148836A1 (en) * | 2007-06-08 | 2008-12-11 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| CN102056904A (zh) * | 2008-06-06 | 2011-05-11 | 欧加农股份有限公司 | 作为ampa受体调节剂的茚满衍生物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW575561B (en) | 1999-03-25 | 2004-02-11 | Hoffmann La Roche | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives |
| ES2320973T3 (es) | 2000-06-12 | 2009-06-01 | EISAI R&D MANAGEMENT CO., LTD. | Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos. |
| AU2003302027A1 (en) | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| WO2006109056A1 (en) | 2005-04-12 | 2006-10-19 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| CA2646585A1 (en) | 2006-03-20 | 2007-09-27 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| EA016415B1 (ru) | 2006-04-24 | 2012-04-30 | Эли Лилли Энд Компани | Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1 |
| TW200817385A (en) * | 2006-07-04 | 2008-04-16 | Organon Nv | Heterocyclic derivatives |
| JP5470557B2 (ja) | 2007-07-26 | 2014-04-16 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成 |
| EP2195303A4 (en) | 2007-09-20 | 2011-07-20 | Cortex Pharma Inc | 3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE AND 3-SUBSTITUTED 1,3-PYRIMIDIONE FOR INCREASING GLUTAMATERGIC SYNAPTIC REACTIONS |
| GB0721094D0 (en) | 2007-10-26 | 2007-12-05 | Glaxo Group Ltd | Compounds |
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
| JP5696037B2 (ja) | 2008-05-01 | 2015-04-08 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター |
| TW201031649A (en) | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives |
| BRPI1014583B1 (pt) | 2009-06-26 | 2020-03-31 | Pfizer, Inc. | Sulfonamidas heterocíclicas e composições farmacêuticas |
| WO2011132051A2 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Tricycle compounds as phosphodiesterase-10 inhibitors |
| UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
-
2017
- 2017-02-10 GB GBGB1702221.1A patent/GB201702221D0/en not_active Ceased
-
2018
- 2018-02-09 US US16/482,791 patent/US11186567B2/en active Active
- 2018-02-09 KR KR1020197024520A patent/KR102665887B1/ko active Active
- 2018-02-09 MX MX2019009537A patent/MX2019009537A/es unknown
- 2018-02-09 RU RU2019126574A patent/RU2019126574A/ru unknown
- 2018-02-09 WO PCT/GB2018/050370 patent/WO2018146486A1/en not_active Ceased
- 2018-02-09 NZ NZ755747A patent/NZ755747A/en unknown
- 2018-02-09 CN CN201880023973.3A patent/CN110520418B/zh active Active
- 2018-02-09 JP JP2019543832A patent/JP7014808B2/ja active Active
- 2018-02-09 AU AU2018218307A patent/AU2018218307C1/en active Active
- 2018-02-09 ES ES18705480T patent/ES2974824T3/es active Active
- 2018-02-09 EP EP18705480.4A patent/EP3580213B1/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008053031A1 (en) * | 2006-11-03 | 2008-05-08 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| WO2008148832A1 (en) * | 2007-06-08 | 2008-12-11 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses therof in medicine |
| WO2008148836A1 (en) * | 2007-06-08 | 2008-12-11 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| CN102056904A (zh) * | 2008-06-06 | 2011-05-11 | 欧加农股份有限公司 | 作为ampa受体调节剂的茚满衍生物 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018218307C1 (en) | 2022-06-23 |
| ES2974824T3 (es) | 2024-07-01 |
| JP7014808B2 (ja) | 2022-02-01 |
| JP2020507592A (ja) | 2020-03-12 |
| US11186567B2 (en) | 2021-11-30 |
| MX2019009537A (es) | 2019-10-04 |
| WO2018146486A1 (en) | 2018-08-16 |
| AU2018218307B2 (en) | 2022-02-24 |
| NZ755747A (en) | 2022-02-25 |
| CA3051647A1 (en) | 2018-08-16 |
| EP3580213B1 (en) | 2024-03-27 |
| RU2019126574A (ru) | 2021-03-10 |
| CN110520418A (zh) | 2019-11-29 |
| BR112019016603A2 (pt) | 2020-03-31 |
| KR20190117549A (ko) | 2019-10-16 |
| AU2018218307A1 (en) | 2019-08-15 |
| EP3580213A1 (en) | 2019-12-18 |
| KR102665887B1 (ko) | 2024-05-10 |
| EP3580213C0 (en) | 2024-03-27 |
| US20210139463A1 (en) | 2021-05-13 |
| RU2019126574A3 (OSRAM) | 2021-03-29 |
| GB201702221D0 (en) | 2017-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2525581T3 (es) | Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje | |
| CN110520418B (zh) | Ampa受体增强剂 | |
| US20250375432A1 (en) | Compounds that modulates ampa receptor function | |
| JP6661605B2 (ja) | ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用 | |
| CN102459252A (zh) | 用于治疗糖原合酶激酶3相关疾病诸如阿尔茨海默病的咪唑取代的嘧啶 | |
| WO2017098367A1 (en) | 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain | |
| CA3051647C (en) | Ampa receptor potentiators | |
| BR112019016603B1 (pt) | Composto, uso deste e uma formulação farmacéutica | |
| HK40044378A (en) | Compounds that modulates ampa receptor function | |
| HK40044378B (en) | Compounds that modulates ampa receptor function | |
| TW201206918A (en) | Chemical compounds | |
| TW201217336A (en) | Chemical compounds | |
| HK1230167B (zh) | 经取代的双环二氢嘧啶酮及其作为嗜中性粒细胞弹性蛋白酶活性的抑制剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20251125 Address after: Britain Patentee after: Dreger Pharmaceutical Co., Ltd. Country or region after: United Kingdom Address before: British husband Patentee before: University COLLEGE CARDIFF CONSULTANTS LIMITED Country or region before: United Kingdom |
|
| TR01 | Transfer of patent right |